Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor for which an IND application has been filed. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies and inflammatory diseases and irreversible PI3K inhibitors.
Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase the probability of success in the clinic while reducing development costs and timelines to registration.
Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house, and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less than 1 year and then advanced to IND in another 9 months.
Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the bench to the market. The company has raised $10 million to date in a Series A financing from GBS Venture Partners, CM Capital Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment Firm. Pathway Therapeutics is located in San Francisco, CA.
Company Details
- Founded
- -
- Address
- 409 Illinois Street, San Francisco,ca 94158,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.pathwaytx.com
- HQ
- San Francisco, Ca
Pathway Therapeutics Ltd Questions
Pathway Therapeutics Ltd's website is http://www.pathwaytx.com
Pathway Therapeutics Ltd's LinkedIn profile is https://www.linkedin.com/company/pathway-therapeutics-ltd
Pathway Therapeutics Ltd's industry is
Biotechnology Research
Pathway Therapeutics Ltd's top competitors are
Vasa Therapeutics,
Aviragen Therapeutics,
Nanospectra Biosciences,
Trophogen,
Hepregen Corporation,
Nanocor Therapeutics, Inc.,
Immunocellular Therapeutics Ltd,
Eragen Biosciences,
Opexa Therapeutics,
Mast Therapeutics, Inc..
Pathway Therapeutics Ltd's categories are Biotechnology Research
Pathway Therapeutics Ltd's founding year is 2008
